newsfilter
← Latest News
Business Wire·

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Announced clear regulatory pathway to Accelerated Approval from U.S. Food and Drug Administration (FDA) for isaralgagene civaparvovec in Fabry disease, using data from ongoing Phase 1/2 STAAR study, avoiding requirement